CPT code 82465 represents the quantitative measurement of total cholesterol in the blood, typically performed using serum or plasma. Cholesterol is a vital lipid, serving as a structural component of cell membranes and a precursor for the synthesis of steroid hormones, bile acids, and Vitamin D. However, elevated levels are a primary risk factor for the development of atherosclerosis and coronary artery disease. The procedure is usually conducted via an automated enzymatic method. In this biochemical process, cholesterol esters in the sample are first hydrolyzed by the enzyme cholesterol esterase into free cholesterol and fatty acids. Subsequently, cholesterol oxidase catalyzes the oxidation of the free cholesterol, producing hydrogen peroxide as a byproduct. This hydrogen peroxide then reacts with a chromogen in the presence of peroxidase to form a colored dye, the intensity of which is proportional to the concentration of cholesterol in the specimen. This colorimetric change is measured using a spectrophotometer at a specific wavelength. Total cholesterol levels provide a composite measure of the cholesterol contained in all lipoprotein fractions, including low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL). While total cholesterol is an essential metric for initial screening and general risk assessment, it is often performed as part of a more comprehensive lipid panel to differentiate between these fractions. Clinical management of patients with dyslipidemia relies heavily on the accuracy of these laboratory measurements to guide dietary interventions, lifestyle modifications, and pharmacological treatments such as statin therapy. Regular monitoring of total cholesterol is indicated for individuals with established cardiovascular disease, hypertension, or diabetes mellitus, as well as those with a strong family history of premature heart disease. It serves as a foundational biomarker in the calculation of various risk scores, such as the Framingham Risk Score or the ASCVD Risk Estimator, which help clinicians determine the appropriate intensity of lipid-lowering therapy.